NBIO - Nascent Biotech, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1953
0.0000 (0.00%)
As of 9:58AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.1953
Open0.1953
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1953 - 0.1953
52 Week Range0.1000 - 0.3575
Volume22,726
Avg. Volume5,266
Market Cap6.542M
Beta (3Y Monthly)-0.39
PE Ratio (TTM)N/A
EPS (TTM)-0.0450
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Nascent Biotech Officers Convert Liability to Stock in the Company

    San Diego, CA, June 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO) announced today that two of its Senior Officers have converted the Company’s liability to them to common stock. Nascent CFO Lowell Holden stated, “I believe the Company has continued to be undervalued and is now positioned to add significant value.  The IND clearance by the FDA, along with the pending commencement of clinical trials, gives me confidence in its growth. Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an IND application before the FDA required for Clinical trials.  Its products are not commercially available.

  • ACCESSWIRE

    Emerging Markets Report: On a Human Level

    Today's featured company Nascent Biotech, Inc. (NBIO) is unique among all our previous offerings. Today's offering is complicated, at least by small cap standards and, well, perhaps typical of a company whose cancer technology has been created and developed since 1982, and which has now just received an incredibly critical permission to enter human trials for brain cancer. In 1982, Japan-based Hideaki Hagiwara, Ph. D was seeking a way to help treat his mother's cervical cancer and approached U.S.-based Dr. Mark Glassy, a professor at UCSD.

  • GlobeNewswire

    Nascent Biotech Moves Corporate Offices to San Diego

    San Diego, CA, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO) has moved their corporate offices to San Diego, CA. Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials in brain cancer.  Its products are not commercially available.

  • GlobeNewswire

    Nascent Biotech Receives Clearance From FDA to Begin Phase I Human Trials in Brain Cancer

    Vero Beach, FL, Dec. 11, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO) received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018.